Chapter 74: Drugs That Weaken the Bacterial Cell Wall II: Other Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, when you think about a medieval siege, the goal is pretty straightforward.

You just bring in the catapults, you smash the castle walls and the fortress falls.

It's, pure indiscriminate brute force.

Yeah, but imagine trying to destroy the enemy's walls while your own troops are like standing shoulder to shoulder with the enemy.

And you somehow have to pull this off without leaving a single scratch on your own soldiers.

Right, which is wild to think about.

That requires a completely different kind of warfare.

You'd need a weapon that specifically recognizes the building materials of the enemy's wall.

Right.

Something completely foreign to your own architecture.

Exactly.

And that concept of selective toxicity is what we are exploiting every single time we prescribe a cell wall inhibitor.

Human cells don't have cell walls.

We just have membranes.

Bacteria, however, rely on a rigid cell wall to keep from absorbing water and bursting open.

If we can smash their walls, we win the siege without harming the human host.

But as any clinician standing at the bedside knows, the bacterial fortress is constantly evolving, you know, mutating and finding new ways to survive our attacks.

Which brings us to our mission for you today.

For you, the advanced practice nursing or physician assistant student listening right now, this deep dive is designed to be your intensive one -on -one tutoring session on chapter 74 of Lane's pharmacotherapeutics.

Specifically, drugs that weaken the bacterial cell wall part two.

Right.

To set our foundation, the central pharmacotherapeutic focus here is on drugs that cause bacterial lysis and death by disrupting that wall.

And with three highly specific exceptions, vancomycin, televansin, and vosfomycin.

Every single medication we cover today belongs to the beta -lactam family of antibiotics.

Okay, let's unpack this.

We have to start with the absolute heavyweights of this chapter.

These are the most widely used group of antibiotics in our arsenal, the cephalosporins.

Yeah, they really are the foundation.

But before we get into the crazy specialized alternatives, I want to understand the mechanics.

How exactly are these beta -lactams breaking down the wall?

Well, they come down to two highly specific simultaneous mechanisms.

Cephalosporins are bactericidal.

They actively kill the bacteria by binding to what we call penicillin binding proteins or PBPs, which are located on the bacterial cell membrane.

PBPs.

Got it.

Yeah.

And when the antibiotic latches onto these PBPs, it disrupts the actual synthesis of the peptidoglycan strands.

It essentially stops the construction crew from laying down new bricks.

But stopping construction isn't enough to kill the cell.

The lethal blow comes from the second mechanism, which is activating auto -license.

Wait, auto -license?

Aren't those the enzymes the bacteria normally use to safely cleave bonds in their own cell wall, so they can expand and grow?

Exactly.

The cephalosporin essentially hijacks the bacteria's own recycling system.

By binding to the PBPs, the drug causes those to just go into overdrive.

Oh, wow.

So the bacteria are rapidly breaking down their own wall, but because the drug halted the construction of new wall material, they can't rebuild it.

So they just tear themselves apart?

Pretty much.

The resultant damage causes the cell to take on water from the surrounding environment, swell and burst.

Osmotic lysis.

But this mechanism creates a key physiological rule you must remember.

Which is?

Because they target the active building and dividing process,

cephalosporins are only effective against bacterial cells that are actively undergoing growth.

Okay, that makes sense.

But the bacteria aren't just sitting there letting us smash their walls, though.

They fight back.

They produce beta -lactamase enzymes, specifically called cephalosporinosis.

Like the bacterial defense system.

I always picture these enzymes as like molecular scissors that the bacteria secrete into their surroundings.

Their only job is to physically snip open the beta -lactam ring of our antibiotic, making it completely useless.

If the bacteria have these chemical scissors, how do our drugs even survive long enough to bind to the PBPs?

Well,

that structural arms race is the entire reason we have five distinct generations of cephalosporins.

You look at the classification tables in the text.

Generations one through five aren't just a list of random drugs.

Right.

They tell a story.

Exactly.

They represent a narrative of progressive chemical engineering to outsmart those bacterial scissors.

As we move from the first generation to the fifth, pharmaceutical chemists tweak the molecular side chains attached to that core beta -lactam ring.

And what did those side chains do?

Those bulky side chains act like a physical shield.

They block the bacterial enzymes from getting close enough to actually snip the ring.

That makes the progression so much easier to visualize.

We are literally building better armor for the drug.

Yes, precisely.

And as you progress through these five generations, you gain three major clinical advantages, right?

Increasing activity against gram -negative bacteria, increasing resistance to destruction by beta -lactamuses, and an increasing ability to penetrate the blood -brain barrier to reach the serp or spinal fluid.

Let's trace that evolution.

First generation, like cephaloxin, what's the clinical profile?

So first generation cephalosporins are highly active against gram -positive bacteria like

streptococci.

But their armor is weak.

Meaning they get cut by the scissors?

Yeah, they have low resistance to beta -lactamuses, and they have poor CSF penetration.

Clinically, they are fantastic for surgical prophylaxis or treating mild, uncomplicated skin infections where we suspect gram -positive bugs.

But if we suspect a gram -negative organism, we need a drug that can penetrate the complex outer membrane of a gram -negative cell envelope.

That pushes us to the second generation, right?

Like sepoxetin.

The second generation offers slightly better gram -negative coverage.

Think hemophilus influenza or klebsiella.

You'll use these for community -acquired pneumonias, otitis, and sinusitis.

But can they reach the brain?

No, their ability to reach the cerebrospinal fluid is still poor.

You cannot use them for meningitis.

Okay, so the third generation is where that limitation shatters.

Drugs like cephotaxime or ceftriaxone.

Oh, the leap to the third generation is massive.

The structural tweaks here provide high gram -negative activity and make them highly resistant to beta -lactamuses.

Most importantly, this is the first generation with the chemical properties required to reliably cross the blood -brain barrier and reach therapeutic bacteriocidal levels in the CSF.

If your patient has bacterial meningitis, you are absolutely pulling from the third generation's shelf.

Then we hit the fourth generation, cephepim.

This is the heavy artillery.

It is.

Cephepim has an incredibly broad spectrum, with the highest activity against gram -negative organisms, including the notoriously difficult Pseudomonas aeruginosa.

This is your go -to for severe hospital -acquired pneumonias and complicated intra -abdominal or urinary tract infections.

Okay, I really want to highlight the fifth generation specifically because it is the ultimate rule -breaker of the beta -lactam world's cephterolin.

Yeah, we definitely need to look at why it's a rule -breaker.

We've talked about bacteria secreting scissors to cut the drug,

but bacteria have a second, even more frustrating defense mechanism.

What's that?

They can alter the actual physical shape of their penicillin -binding proteins.

They essentially mutate the lox or a key no longer fits.

That is exactly what MRSA mythicillin -resistant Staphylococcus aureus does.

It produces a mutated PBP called PBP2A.

Every other cephalosporin just bounces right off it.

Cephterolin is the only cephalosporin engineered with a unique affinity to bind tightly to those altered PBPs.

So it's specifically utilized for MRSA -associated infections.

That's brilliant.

It really is.

But, you know, manipulating these drug structures to kill bacteria better also means we occasionally alter how they interact with the human body.

To prescribe these safely, we have to talk pharmacokinetics.

Why are we giving the vast majority of these drugs via IV or IM injection?

Well, the core beta -lactam structure of most cephalosporins is easily destroyed by stomach acid, which results in terrible absorption for the gastrointestinal tract.

Out of all the cephalosporins used in the U .S., only a handful can be given orally.

Got it.

Once injected into the body, they distribute widely.

But elimination is the critical monitoring parameter here.

Practically all cephalosporins are clear from the body by the kidneys.

Meaning if my patient has renal insufficiency,

their kidneys aren't filtering the drug out.

It's just circulating and accumulating to toxic levels.

Exactly.

You must proactively reduce the dosage of most cephalosporins for patients with declining renal function.

However, the text points out one major board testable exception.

Which is?

Ceftriaxone.

Ceftriaxone is eliminated largely by the liver, excreted through the biliary tract.

Therefore, dosage reduction is entirely unnecessary in patients with renal impairment.

Oh, wow.

That is a massive clinical pearl when you're staring at a patient's elevated creatinine levels.

It saves a lot of complicated math, that's for sure.

Absolutely.

Let's move to patient safety and adverse effects.

Starting with the allergy that terrifies a lot of students, penicillin cross -reactivity.

Penicillins and cephalosporins share that core beta -lactam ring.

The book says only about 1 % of penicillin -allergic patients will react to a cephalosporin.

Right.

It's very low.

I have to stop you there, though, because 1 % is still 1 in 100 patients.

If I see penicillin allergy glowing red on the electronic chart, my immediate clinical instinct is to just pick a different drug class entirely.

Why are we risking it?

I get that instinct, but it comes down to balancing that small risk against the immense clinical benefit of cephalosporins and really understanding the nature of the allergy itself.

Okay, walk me through that.

For a patient who reports a mild penicillin allergy, maybe they had a flat maculopapular rash 10 years ago, cephalosporins can generally be administered with minimal concern.

The risk of cross -reactivity there is incredibly low.

However, the clinical threshold for a hard stop is a history of severe IG -mediated anaphylaxis.

If the patient had throat swelling, highs, or shortness of breath with penicillin, cephalosporins are absolutely contraindicated, because in that case, that 1 % cross -reaction could be fatal.

That makes a lot of sense.

The text also outlines some bizarre side effects that you wouldn't intuitively link to an antibiotic, like bleeding and alcohol intolerance.

Walk me through the pathophysiology of those interactions.

Sure.

Let's start with bleeding.

Three specific cephalosporins, cephatentin, cephasolin, and cephtriaxone, contain a unique chemical side chain called an NMTT side chain.

NMTT?

Yeah, and this specific molecular appendage interferes with vitamin K metabolism in the body.

Vitamin K is a necessary cofactor for the liver to synthesize several vital clotting factors.

By disrupting that recycling process, these specific drugs impair clot formation, putting the patient at risk for hemorrhage.

Wait, so combining cephatentin, cephasolin, or cephriaxone with n -acides, or systemic anticoagulants, or thrombolytics, you are just stacking bleeding risks on top of each other.

Exactly.

You must monitor their prothrombin time and look for any signs of hidden bleeding.

And what about the alcohol interaction?

The alcohol interaction is equally fascinating.

Cephasolin and cephatentin can induce a dangerous disulfiram -like reaction.

These drugs inhibit an enzyme called aldehyde dehydrogenase.

Normally your body breaks alcohol down into acetaldehyde, and then aldehyde dehydrogenase clears it.

But the drug stops that.

Right, because the antibiotic blocks that clearing enzyme.

Acetaldehyde builds up in the blood to toxic levels.

So if my patient is on cephasolin and has a glass of wine with dinner, they are going to experience severe flushing, nausea, vomiting, sweating,

and potentially dangerous hypotension.

I need to explicitly interrogate them about their weekend plans before writing that script.

Absolutely.

They must avoid alcohol in any form.

And just to round out our person -centered care guidelines here, cephalosporins are generally safe across the lifespan, including in pregnancy and breastfeeding.

But as we discussed with elimination, doses almost always need to be adjusted for older adults.

Just purely because their baseline glomerular filtration rate naturally declines with age.

Exactly right.

Okay, sometimes a patient comes in with an infection so severe or so deeply mixed with different organisms that even our advanced cephalosporins fail.

We need the absolute broadest coverage possible.

We need the carbapenems.

Yes, an imapenem is our prototype carbapenem.

Its antimicrobial spectrum is broader than practically all other antimicrobial drugs.

Wow.

It effortlessly penetrates the gram -negative cell envelope and binds to two different PVPs, completely shutting down cell wall synthesis.

It is highly active against gram -positive kochi, gram -negative kochi and bacilli, and anaerobic bacteria.

It is the ultimate mixed infection drug.

But despite being this massive broad -spectrum powerhouse, none of the carbapenems have any activity against MRSA.

Imapenem is useless against it.

That's right.

The mutated PVPs of MRSA simply do not bind with carbapenems.

You just cannot use them for that indication.

You know, I have a bone to pick with Imapam's clinical packaging.

Whenever you order it, it's packaged under the trade name Primaxin, which is a combination of imapenem and a second drug called psilastatin.

Why does imapenem need a sidekick?

What does psilastatin actually do?

It's actually an elegant pharmacokinetic solution to a physiological problem.

Imapenem is incredibly effective, but it has a fatal flaw regarding elimination.

When it travels to the kidneys to be excreted, it encounters an enzyme in the renal tubules called depeptidase.

Depeptidase essentially destroys the imapenem before it can achieve therapeutic levels in the urine or be effectively cleared.

So if you have a severe urinary tract infection, the drug gets metabolized and deactivated right as it reaches the battleground.

Exactly.

So psilastatin is a specific dipeptidase inhibitor.

It has absolutely no antibacterial activity of its own.

It acts purely as imapenem's bodyguard, binding the renal enzyme and neutralizing it so the imapenem can pass through the kidneys intact and maintain its therapeutic concentration.

That makes perfect sense.

What are the clinical safety alerts with imapenem?

There is a severe drug interaction humans memorize.

Imapenem can dramatically reduce blood levels of valproate, which is a common medication used to control seizures.

Yeah, if you administer imapenem to a patient on valproate, their serum levels will drop rapidly and they risk experiencing breakthrough seizures.

Second, regarding resistance.

If you are treating a known pseudomonas ervujosa infection, imapenem cannot be used as monotherapy.

It must be combined with another anti -pseudomonas drug because resistance emerges incredibly rapidly if it's used alone.

Good to know.

Well, we've covered the broad spectrum powerhouses.

Now we need to talk about our specialized sniper, the drug we pull out when the beta -lactams just aren't cutting it or when the patient has a severe allergy.

We are stepping entirely outside the beta -lactam family to look at vancomycin.

Vancomycin is arguably the most widely used antibiotic in US hospitals.

And structurally, it is completely unrelated to anything we've discussed so far.

It does not have a beta -lactam ring.

Wait, if it doesn't have a beta -lactam ring, it can't bind to PVPs.

How is it smashing the cell wall?

Instead of binding to the enzymes that build the wall,

vancomycin binds directly to the precursor molecules, the D -alanine building blocks themselves.

So it literally steals the bricks before the builder can lay them down.

That's exactly it.

It halts cell wall synthesis by taking the materials away.

Because of this unique mechanism and because the molecule itself is massive and bulky, it cannot cross the outer membrane of gram -negative bacteria.

So it's active only against gram -positive organisms.

Right.

It is our primary weapon for severe MRSA infections and severe Clostridioids difficile or C.

diff.

You know, there is a really fascinating pharmacokinetic quirk with vancomycin that dictates how we treat C.

diff.

Because vancomycin is such a massive molecule, it has terrible gastrointestinal absorption.

Like if you swallow it, almost none of it enters the bloodstream.

Which perfectly aligns with our therapeutic goals.

For a systemic infection like MRSA in the blood or lungs, you have no choice.

You must administer vancomycin intravenously.

But if you have an intestinal infection, specifically C.

diff, you administer it orally.

Oh, because you want the drug to stay in the gut.

Precisely.

You want the large, unobsorbed drug molecules to stay trapped in the GI tract,

baiting the lining of the intestine, right where the C.

diff.

bacteria are colonizing, without exposing the rest of the body to the drug.

Let's talk about monitoring parameters, though, because IV vancomycin is highly toxic to the kidneys.

Renal failure is the primary danger, and the risk is entirely dose -related.

To prevent kidney damage, you must routinely monitor trough serum levels.

The lowest concentration of the drug in the blood, drawn immediately before the next dose is infused.

The trough must be high enough to ensure bacterial eradication, but low enough to avoid nephrotoxicity.

You also must avoid using other nephrotoxic drugs concurrently, like NSAIDs or aminoglycosides.

What's the threshold for action there?

When do we actually alter the dose?

The clinical benchmark provided in the text is a 50 % increase in baseline serum creatinine levels.

If creatinine jumps by 50%, significant kidney damage is occurring, and the vancomycin dosage must be immediately reduced.

Let's zoom in on that C.

diff.

application,

because the IBSA clinical guidelines detailed in table 74 .6 are incredibly specific.

C.

diff.

is an absolute nightmare, a gram -positive, spore -forming anaerobic bacillus.

But the pathophysiology of how the infection starts is usually iatrogenic, right?

We cause it.

Sadly,

yes.

C.

diff.

infections are almost always preceded by the use of broad -spectrum antibiotics,

especially fluoroquinolones, clindamycin, or second - and third -generation cephalosporins.

Because they wipe everything out.

Exactly.

When we administer these drugs, we indiscriminately wipe out the normal, healthy flora in the patient's gut.

Without those healthy bacteria competing for space and nutrients,

dormant C.

diff.

spores in the intestine suddenly have room to flourish.

They multiply and release two potent toxins, Toxin A and Toxin B, which violently attack the lining of the colon.

As an infection control priority, and this is something every clinician needs to hear, loud and clear alcohol -based hand rubs do absolutely nothing to C.

diff.

spores.

Nothing at all.

The spores have a tough, dormant protein coat that alcohol cannot penetrate.

If you examine a patient with C.

diff., you must wash your hands with soap and running water.

The soap doesn't kill the spores either, but the physical friction of scrubbing and the volume of water physically dislodges them and flushes them down the drain.

Hand sanitizer is useless here.

It's a huge safety priority.

So how do we actually treat it once it takes hold?

According to the IDSA algorithm, Step 1 is always to discontinue the offending antibiotic that wiped out the gut flora in the first place.

For some mild cases, restoring the normal flora is enough.

But if they need pharmacotherapy?

If pharmacotherapy is required for an initial, mild or moderate episode, the guidelines recommend starting with oral vancomycin or oral fidexomycin.

What if the patient crashes, like they hit that fulminant stage with severe shock, profound hypotension or toxic megacolon?

For fulminant cases, you must escalate aggressively.

You use high -dose oral vancomycin.

And if the patient has an alias, meaning their bowel has stopped moving entirely, giving a drug orally won't help because it'll just sit in the stomach.

Right.

It won't reach the colon.

Exactly.

In that scenario, you administer vancomycin both orally and regularly, via an enema, to ensure the drug reaches the affected colon tissue.

Even with perfect treatment, C.

diff has a brutal recurrence rate.

It does.

Around 15 to 30 % of patients will experience a recurrence as dormant spores reactivate.

For these recurrences, the guidelines suggest a pulsed, tapered regimen of vancomycin to slowly wean them off, or transitioning to fidexomycin.

Are there any other options?

For highly refractory cases, we can introduce monoclonal antibodies like Bezlotoxamab.

It doesn't kill the bacteria, but it binds directly to the C.

diff toxins to neutralize the damage.

Okay, we have to touch on the highly specialized alternatives that finish out this chapter.

These are the drugs you reach for when vancomycin fails, or when a patient's kidneys are already shutting down.

The first one is televansin.

Televansin is a synthetic derivative of vancomycin.

It belongs to a new class called lipoglycoproteins.

What's fascinating here is its dual mechanism of action.

It inhibits cell wall synthesis, just like vancomycin, but its lipophagous side chain also binds directly to the bacterial cell membrane.

So it physically disrupts membrane function too.

Yes, it causes the cellular contents to just leak out.

It's essentially attacking the wall and the foundation at the same time.

But the adverse effects are so strange.

Patients frequently report taste disturbances, nausea, and notably foamy urine.

Yeah, the foamy urine is a classic side effect to watch for.

It can also prolong the QT interval, meaning you have to be extremely cautious prescribing it to patients with cardiac arrhythmias.

But the most critical piece of information for televansin is its FDA black box warning.

This requires profound clinical reasoning regarding risk versus benefit.

Walk us through the warning.

Televansin carries a black box warning for increased mortality compared to vancomycin in patients being treated for hospital -acquired or ventilator -associated bacterial pneumonia who have a creatinine clearance of less than 50 milliliters per minute.

Meaning if their kidneys are failing, this drug has a higher risk of killing the patient than the alternative.

Precisely.

It also carries a black box warning for adverse developmental outcomes in pregnancy.

Wow.

Those black box warnings absolutely dictate your prescribing limits.

Okay, next specialized alternative, Astrionem.

Astrionem belongs to a class called monobactams.

It still contains a beta -lactam ring, but structurally the ring is unfused.

It stands completely alone.

It binds specifically to PDP3, which means it is active only against gram -negative aerobes.

It has absolutely zero activity against gram -positive bacteria or anaerobes.

But the clinical application here isn't just about its narrow spectrum, right?

It's about the shape of that unfused ring.

Because it stands alone, its physical structure is so wildly different from penicillins and

cephalosporins that the human immune system doesn't recognize it as a relative.

There is virtually no cross -allergenicity.

So if you have a patient with a documented severe anaphylactic allergy to penicillins or cephalosporins -like,

the patient who stops breathing when they see a beta -lactam is considered a safe alternative.

It's a lifesaver in those exact scenarios.

And our final drug to dissect is phosphomycin.

Right, phosphomycin.

It disrupts the synthesis of peptidoglycan polymer strands earlier in the process than beta -lactams.

It's approved as a single -dose solution for uncomplicated urinary tract infections in women.

I have to admit, phosphomycin scares me a bit as a provider.

Why is that?

Well, if I give a patient a single dose on Monday and she calls me on Tuesday afternoon saying she is still burning when she pees, my immediate clinical instinct is that the single dose failed.

Like, the bacteria survived and I need to hit the infection again with a second dose.

Are you saying I just tell her to wait?

That is the hardest part of prescribing it, but yes.

The text explicitly warns against a second dose.

Patient education is the primary intervention here.

You must tell the patient up front, before they leave the clinic, that phosphomycin takes two to three days for symptoms to fully resolve.

Two to three days, okay.

The drug actively kills the bacteria quickly,

but the intense mucosal inflammation in the bladder takes time to subside.

Prescribing an additional dose will not speed up their recovery.

It will only drastically increase the risk of adverse effects like severe diarrhea, vaginitis, and headache.

So you just have to hold the line and let the biology work.

Exactly.

Let's step back and look at the journey we've taken today.

We started with the incredibly broad application of the five generations of cephalosporins, learning how manipulating molecular side chains built armor against bacterial scissors,

and allowed us to penetrate the blood -brain barrier.

We did.

We unpacked the heavy -hitting carbapenems and the elegant physiological workaround of using psilastatin to protect imapenem in the kidneys.

We drilled down into the highly specific mechanisms of vancomycin for MRSA, the iatrogenic nightmare of C.

diff, and finished with the specialized structural solutions of televansin, astreonim, and phosphomycin.

As we wrap up this deep dive, I want to leave you with a thought regarding the bigger picture of infectious disease.

Let's hear it.

We spent this entire session marveling at the incredibly complex molecules we designed to evade bacterial defenses,

engineering new generations to bypass beta -lactamases, or creating cifteraline specifically to bind altered PVPs.

But we have to recognize that every single time we prescribe these antibiotics,

we're acting as the selective evolutionary pressure that forces these bacteria to adapt.

We are effectively training the enemy.

We are.

The text highlights this beautifully.

Our intense widespread use of broad -spectrum fluoroquinolones and cephalosporins didn't just cause occasional C.

diff infections.

It directly fueled a rapid spread of the NAP1BI027 strain of C.

diff.

That's the hypervirulent one, right?

Yes.

A mutated strain that produces massively more toxin than older variants.

So the provocative question you must carry into your clinical practice is this.

How will the prescribing choices you make today shape the lethal resistance patterns of tomorrow?

It is a heavy responsibility to hold that pen or sign that electronic order.

But with the clinical reasoning and foundational pathophysiology you're building right now, you are ready for it.

Thank you so much for joining us for this intensive study session.

On behalf of the Last Minute Lecture team, trust your preparation, keep your patience at the center of your decisions, and we'll catch you on the next deep dive.